Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice

被引:0
作者
Robert Haupt
Lauren Baracco
Erin M. Harberts
Madhumathi Loganathan
Lucas J. Kerstetter
Florian Krammer
Lynda Coughlan
Robert K. Ernst
Matthew B. Frieman
机构
[1] University of Maryland,Department of Microbiology and Immunology, School of Medicine
[2] University of Maryland,Center for Pathogen Research, School of Medicine
[3] University of Maryland,Department of Microbial Pathogenesis, School of Dentistry
[4] Icahn School of Medicine,Department of Microbiology
[5] Icahn School of Medicine at Mount Sinai,Center for Vaccine Research and Pandemic Preparedness (C
[6] Icahn School of Medicine at Mount Sinai,VARPP)
[7] University of Maryland School of Medicine,Department of Pathology, Molecular and Cell Based Medicine
[8] USAMRIID,Center for Vaccine Development and Global Health (CVD)
来源
Scientific Reports | / 13卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Influenza A virus (IAV) is a leading cause of respiratory disease worldwide often resulting in severe morbidity and mortality. We have previously shown that the Bacterial Enzymatic Combinatorial Chemistry (BECC) adjuvants, BECC438 and BECC470, formulated with an influenza virus hemagglutinin (HA) protein vaccine, offer greater protection from influenza virus challenge in mouse respiratory models using adult mice than standard HA:adjuvant combinations. In this study, we determined that immunization with HA + BECC adjuvants also significantly broadened the epitopes targeted on HA as compared with other adjuvants, resulting in increased titers of antibodies directed against the highly conserved HA stalk domain. Importantly, we demonstrate that BECC470 combined with an influenza virus HA protein antigen in a prime-only immunization regimen was able to achieve complete protection from challenge in a ~ 12-month-old mouse aged model. Together, this demonstrates the heightened protection provided by the BECC470 adjuvant in an influenza virus vaccine model and shows the enhanced immune response, as compared to other adjuvants elicited by the formulation of HA with BECC470.
引用
收藏
相关论文
共 46 条
[1]  
Krammer F(2019)The human antibody response to influenza A virus infection and vaccination Nat. Rev. Immunol. 19 383-397
[2]  
Merced-Morales A(2022)Influenza activity and composition of the 2022–23 influenza vaccine—United States, 2021–22 season MMWR Morb. Mortal. Wkly. Rep. 71 913-919
[3]  
Chung JR(2022)Interim estimates of 2021–22 seasonal influenza vaccine effectiveness—United States, February 2022 MMWR Morb. Mortal. Wkly. Rep. 71 365-370
[4]  
Kirkpatrick E(2018)The influenza virus hemagglutinin head evolves faster than the stalk domain Sci. Rep. 8 10432-2634
[5]  
Esposito S(2022)Efficacy and safety of a quadrivalent influenza vaccine in children aged 6–35 months: A global, multiseasonal, controlled, randomized Phase III study Vaccine 40 2626-1321
[6]  
Gustafson CE(2020)Influence of immune aging on vaccine responses J. Allergy Clin. Immunol. 145 1309-5029
[7]  
Kelly H(2010)Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010 Euro Surveill. 15 5023-395
[8]  
Mimura W(2022)Influenza vaccine effectiveness against hospitalization during the 2018/2019 season among older persons aged >/=75 years in Japan: The LIFE-VENUS Study Vaccine 40 386-1520
[9]  
Ishiguro C(2019)Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season Euro Surveill. 24 1516-6295
[10]  
Fukuda H(2018)Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17 Euro Surveill. 23 6291-475